This study examines how lipophilic-modified antisense oligonucleotides (ASOs) enhance exon skipping in Duchenne muscular dystrophy (DMD). The results show improved cellular uptake, nanoparticle formation, and higher exon-skipping efficiency, making these ASOs promising therapeutic candidates.